Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE3.5900
- TODAY'S CHANGE (%)0.1400 (4.0580%)
- Bid / Lots3.4500/ 1
- Ask / Lots3.6100/ 11
- Open / Previous Close3.4000 / 3.4500
- Day Range
- 52 Week Range
- Volume298,573
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 5382 | 3.46 |
| 09:34 ET | 240 | 3.46 |
| 09:36 ET | 300 | 3.45 |
| 09:38 ET | 700 | 3.45 |
| 09:39 ET | 350 | 3.45 |
| 09:41 ET | 250 | 3.455 |
| 09:45 ET | 100 | 3.45 |
| 09:48 ET | 300 | 3.45 |
| 09:50 ET | 700 | 3.45 |
| 09:52 ET | 830 | 3.46 |
| 09:54 ET | 700 | 3.45 |
| 09:56 ET | 1768 | 3.45 |
| 09:57 ET | 2710 | 3.45 |
| 09:59 ET | 1528 | 3.45 |
| 10:01 ET | 1045 | 3.4559 |
| 10:03 ET | 474 | 3.455 |
| 10:06 ET | 200 | 3.4584 |
| 10:08 ET | 100 | 3.455 |
| 10:10 ET | 12335 | 3.455 |
| 10:12 ET | 2211 | 3.475 |
| 10:14 ET | 2938 | 3.48 |
| 10:15 ET | 1047 | 3.495 |
| 10:17 ET | 3600 | 3.5 |
| 10:19 ET | 1135 | 3.515 |
| 10:21 ET | 250 | 3.5015 |
| 10:24 ET | 160 | 3.5099 |
| 10:26 ET | 1802 | 3.51 |
| 10:30 ET | 1950 | 3.505 |
| 10:32 ET | 500 | 3.501 |
| 10:33 ET | 300 | 3.51 |
| 10:35 ET | 200 | 3.505 |
| 10:37 ET | 2901 | 3.521 |
| 10:39 ET | 2408 | 3.505 |
| 10:42 ET | 2400 | 3.51 |
| 10:44 ET | 6710 | 3.525 |
| 10:46 ET | 100 | 3.525 |
| 10:48 ET | 5434 | 3.515 |
| 10:50 ET | 2500 | 3.51 |
| 10:51 ET | 2200 | 3.52 |
| 10:53 ET | 402 | 3.515 |
| 10:57 ET | 800 | 3.515 |
| 11:00 ET | 2164 | 3.52 |
| 11:02 ET | 3001 | 3.52 |
| 11:04 ET | 200 | 3.525 |
| 11:06 ET | 500 | 3.525 |
| 11:08 ET | 1700 | 3.515 |
| 11:09 ET | 480 | 3.515 |
| 11:11 ET | 989 | 3.505 |
| 11:13 ET | 8405 | 3.52 |
| 11:18 ET | 1800 | 3.515 |
| 11:20 ET | 1400 | 3.515 |
| 11:22 ET | 10589 | 3.52 |
| 11:24 ET | 3989 | 3.52 |
| 11:26 ET | 1500 | 3.525 |
| 11:27 ET | 1100 | 3.525 |
| 11:31 ET | 3057 | 3.5175 |
| 11:33 ET | 3500 | 3.52 |
| 11:38 ET | 5001 | 3.525 |
| 11:40 ET | 700 | 3.52 |
| 11:42 ET | 6790 | 3.53 |
| 11:44 ET | 1700 | 3.52 |
| 11:45 ET | 700 | 3.52 |
| 11:47 ET | 1294 | 3.51 |
| 11:49 ET | 5712 | 3.51 |
| 11:51 ET | 1210 | 3.51 |
| 11:54 ET | 450 | 3.5192 |
| 11:56 ET | 2000 | 3.515 |
| 11:58 ET | 2120 | 3.51 |
| 12:00 ET | 695 | 3.51 |
| 12:02 ET | 8537 | 3.53 |
| 12:05 ET | 2635 | 3.545 |
| 12:07 ET | 2800 | 3.545 |
| 12:09 ET | 1200 | 3.5499 |
| 12:12 ET | 11643 | 3.52 |
| 12:16 ET | 720 | 3.525 |
| 12:18 ET | 414 | 3.525 |
| 12:20 ET | 200 | 3.525 |
| 12:21 ET | 1000 | 3.53 |
| 12:23 ET | 250 | 3.52 |
| 12:25 ET | 1000 | 3.52 |
| 12:27 ET | 100 | 3.525 |
| 12:30 ET | 550 | 3.5238 |
| 12:32 ET | 2801 | 3.545 |
| 12:34 ET | 2000 | 3.545 |
| 12:36 ET | 500 | 3.5499 |
| 12:38 ET | 4083 | 3.5505 |
| 12:39 ET | 200 | 3.5501 |
| 12:41 ET | 800 | 3.55 |
| 12:45 ET | 1300 | 3.55 |
| 12:48 ET | 10702 | 3.545 |
| 12:50 ET | 3098 | 3.565 |
| 12:52 ET | 800 | 3.57 |
| 12:54 ET | 15911 | 3.565 |
| 12:56 ET | 2802 | 3.575 |
| 12:57 ET | 7200 | 3.595 |
| 12:59 ET | 24277 | 3.59 |
Jun 20, 2024
DJ Mereo BioPharma Group Is Maintained at Outperform by Leerink Partners, from 8:19AM ET on Thursday Jun 20, 2024 by Dow Jones
8:19AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 14, 2024
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market, from 7:50AM ET on Friday Jun 14, 2024 by Dow Jones
7:50AM ET on Friday Jun 14, 2024 by Dow JonesPress Release: Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market, from 7:50AM ET on Friday Jun 14, 2024 by Dow Jones
7:50AM ET on Friday Jun 14, 2024 by Dow Jones
Jun 13, 2024
DJ Mereo BioPharma Group Initiated at Outperform by Baird, from 5:27AM ET on Thursday Jun 13, 2024 by Dow Jones
5:27AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 12:25PM ET on Wednesday Jun 12, 2024 by Dow Jones
12:25PM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 551.0M | -11.4x | --- |
Immunome Inc | 726.8M | -2.2x | --- |
AnaptysBio Inc | 680.2M | -4.1x | --- |
SS Innovations International Inc | 708.6M | -30.3x | --- |
Stoke Therapeutics Inc | 660.4M | -5.2x | --- |
Praxis Precision Medicines Inc | 684.3M | -2.5x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Director
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $551.0M |
|---|---|
Revenue (TTM) | $10.1M |
Shares Outstanding | 152.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-0.32 |
Book Value | $0.45 |
P/E Ratio | -11.4x |
Price/Sales (TTM) | 54.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
